Medigen Vaccine Biologics Statistics
Total Valuation
Medigen Vaccine Biologics has a market cap or net worth of TWD 15.78 billion. The enterprise value is 14.28 billion.
Market Cap | 15.78B |
Enterprise Value | 14.28B |
Important Dates
The next estimated earnings date is Friday, November 1, 2024.
Earnings Date | Nov 1, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Medigen Vaccine Biologics has 328.65 million shares outstanding. The number of shares has increased by 0.31% in one year.
Shares Outstanding | 328.65M |
Shares Change (YoY) | +0.31% |
Shares Change (QoQ) | +0.03% |
Owned by Insiders (%) | 0.21% |
Owned by Institutions (%) | 3.28% |
Float | 255.82M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 25.30 |
PB Ratio | 4.10 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -20.58 |
EV / Sales | 22.91 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -59.46 |
Financial Position
The company has a current ratio of 11.99, with a Debt / Equity ratio of 7.42.
Current Ratio | 11.99 |
Quick Ratio | 9.39 |
Debt / Equity | 7.42 |
Debt / EBITDA | n/a |
Debt / FCF | -1.19 |
Interest Coverage | -22.12 |
Financial Efficiency
Return on equity (ROE) is -16.64% and return on invested capital (ROIC) is -8.76%.
Return on Equity (ROE) | -16.64% |
Return on Assets (ROA) | -8.47% |
Return on Capital (ROIC) | -8.76% |
Revenue Per Employee | 6.05M |
Profits Per Employee | -6.74M |
Employee Count | 103 |
Asset Turnover | 0.11 |
Inventory Turnover | 0.29 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.60% in the last 52 weeks. The beta is 0.77, so Medigen Vaccine Biologics's price volatility has been lower than the market average.
Beta (5Y) | 0.77 |
52-Week Price Change | -34.60% |
50-Day Moving Average | 47.92 |
200-Day Moving Average | 56.12 |
Relative Strength Index (RSI) | 50.27 |
Average Volume (20 Days) | 744,406 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Medigen Vaccine Biologics had revenue of TWD 623.45 million and -694.03 million in losses. Loss per share was -2.11.
Revenue | 623.45M |
Gross Profit | 415.57M |
Operating Income | -742.18M |
Pretax Income | -694.03M |
Net Income | -694.03M |
EBITDA | -624.74M |
EBIT | -742.18M |
Loss Per Share | -2.11 |
Balance Sheet
The company has 1.78 billion in cash and 285.56 million in debt, giving a net cash position of 1.49 billion or 4.54 per share.
Cash & Cash Equivalents | 1.78B |
Total Debt | 285.56M |
Net Cash | 1.49B |
Net Cash Per Share | 4.54 |
Equity (Book Value) | 3.85B |
Book Value Per Share | 11.70 |
Working Capital | 2.31B |
Cash Flow
In the last 12 months, operating cash flow was -205.37 million and capital expenditures -34.89 million, giving a free cash flow of -240.26 million.
Operating Cash Flow | -205.37M |
Capital Expenditures | -34.89M |
Free Cash Flow | -240.26M |
FCF Per Share | -0.73 |
Margins
Gross margin is 66.66%, with operating and profit margins of -119.04% and -111.32%.
Gross Margin | 66.66% |
Operating Margin | -119.04% |
Pretax Margin | -111.32% |
Profit Margin | -111.32% |
EBITDA Margin | -100.21% |
EBIT Margin | -119.04% |
FCF Margin | -38.54% |
Dividends & Yields
Medigen Vaccine Biologics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.31% |
Shareholder Yield | -0.31% |
Earnings Yield | -4.40% |
FCF Yield | -1.52% |
Stock Splits
The last stock split was on August 3, 2022. It was a forward split with a ratio of 1.48280574.
Last Split Date | Aug 3, 2022 |
Split Type | Forward |
Split Ratio | 1.48280574 |